We have tested three human monoclonal antibodies (MAbs) IgG1b12, 2G12, and 2F5) to the
envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1), and a tetrameric …

Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …

IgG1b12, a human monoclonal antibody (MAb) to an epitope overlapping the CD4-binding
site on gp120, has broad and potent neutralizing activity against most primary human …

Human monoclonal antibody 447-52D binds to the V3 determinant of the human
immunodeficiency virus type 1 (HIV-1) gp120 external glycoprotein. Its binding requires the …

The third variable region (V3) of the HIV-1 gp120 envelope glycoprotein is thought to induce
potent neutralizing antibodies which are generally defined as type specific and reactive with …

The ability of antibodies to the V3 region and the CD4-binding domain (CD4bd) of human
immunodeficiency virus type 1 (HIV-1) to act in synergy to neutralize HIV has been …

A collaborative study was organized to identify monoclonal antibodies (MAbs) that may be
broadly and potently neutralizing for a panel of human immunodeficiency virus type 1 (HIV …

The CD4-binding domain of human immunodeficiency virus type 1 (HIV-1) gp120 elicits
antibodies that are present in infected human sera. Monoclonal antibodies that recognize …

We have used virus neutralization and antibody-binding techniques to define the epitope for
a human monoclonal antibody, designated 19b, within the V3 region of the gp120 surface …

The identification and characterization of new human monoclonal antibodies (hMAbs) able
to neutralize primary human immunodeficiency virus type 1 (HIV-1) isolates from different …